Long COVID-19 Pulmonary Sequelae and Management Considerations
The human coronavirus 2019 disease (COVID-19) and the associated acute respiratory distress syndrome (ARDS) are responsible for the worst global health crisis of the last century. Similarly, to previous coronaviruses leading to past pandemics, including severe acute respiratory syndrome (SARS) and m...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-08-01
|
| Series: | Journal of Personalized Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4426/11/9/838 |
| _version_ | 1797518575188049920 |
|---|---|
| author | Afroditi K. Boutou Andreas Asimakos Eleni Kortianou Ioannis Vogiatzis Argyris Tzouvelekis |
| author_facet | Afroditi K. Boutou Andreas Asimakos Eleni Kortianou Ioannis Vogiatzis Argyris Tzouvelekis |
| author_sort | Afroditi K. Boutou |
| collection | DOAJ |
| description | The human coronavirus 2019 disease (COVID-19) and the associated acute respiratory distress syndrome (ARDS) are responsible for the worst global health crisis of the last century. Similarly, to previous coronaviruses leading to past pandemics, including severe acute respiratory syndrome (SARS) and middle east respiratory syndrome (MERS), a growing body of evidence support that a substantial minority of patients surviving the acute phase of the disease present with long-term sequelae lasting for up to 6 months following acute infection. The clinical spectrum of these manifestations is widespread across multiple organs and consists of the long-COVID-19 syndrome. The aim of the current review is to summarize the current state of knowledge on the pulmonary manifestations of the long COVID-19 syndrome including clinical symptoms, parenchymal, and functional abnormalities, as well as highlight epidemiology, risk factors, and follow-up strategies for early identification and timely therapeutic interventions. The literature data on management considerations including the role of corticosteroids and antifibrotic treatment, as well as the therapeutic potential of a structured and personalized pulmonary rehabilitation program are detailed and discussed. |
| first_indexed | 2024-03-10T07:31:45Z |
| format | Article |
| id | doaj.art-3a79e55ed6a24694ba88dd73fb501255 |
| institution | Directory Open Access Journal |
| issn | 2075-4426 |
| language | English |
| last_indexed | 2024-03-10T07:31:45Z |
| publishDate | 2021-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Personalized Medicine |
| spelling | doaj.art-3a79e55ed6a24694ba88dd73fb5012552023-11-22T13:49:52ZengMDPI AGJournal of Personalized Medicine2075-44262021-08-0111983810.3390/jpm11090838Long COVID-19 Pulmonary Sequelae and Management ConsiderationsAfroditi K. Boutou0Andreas Asimakos1Eleni Kortianou2Ioannis Vogiatzis3Argyris Tzouvelekis4Department of Respiratory Medicine, “G. Papanikolaou” Hospital, 57010 Thessaloniki, GreeceCritical Care Department and Pulmonary Unit, Evangelismos Hospital, Medical School, National and Kapodistrian University of Athens, 10676 Athens, GreecePhysiotherapy Department, University of Thessaly, 35100 Lamia, GreeceDepartment of Sport, Exercise and Rehabilitation, Northumbria University, Newcastle NE1 8ST, UKDepartment of Respiratory Medicine, University Hospital of Patras, 26504 Patras, GreeceThe human coronavirus 2019 disease (COVID-19) and the associated acute respiratory distress syndrome (ARDS) are responsible for the worst global health crisis of the last century. Similarly, to previous coronaviruses leading to past pandemics, including severe acute respiratory syndrome (SARS) and middle east respiratory syndrome (MERS), a growing body of evidence support that a substantial minority of patients surviving the acute phase of the disease present with long-term sequelae lasting for up to 6 months following acute infection. The clinical spectrum of these manifestations is widespread across multiple organs and consists of the long-COVID-19 syndrome. The aim of the current review is to summarize the current state of knowledge on the pulmonary manifestations of the long COVID-19 syndrome including clinical symptoms, parenchymal, and functional abnormalities, as well as highlight epidemiology, risk factors, and follow-up strategies for early identification and timely therapeutic interventions. The literature data on management considerations including the role of corticosteroids and antifibrotic treatment, as well as the therapeutic potential of a structured and personalized pulmonary rehabilitation program are detailed and discussed.https://www.mdpi.com/2075-4426/11/9/838Post-COVID sequelaeparenchymal abnormalitiesfunctional limitationrehabilitation |
| spellingShingle | Afroditi K. Boutou Andreas Asimakos Eleni Kortianou Ioannis Vogiatzis Argyris Tzouvelekis Long COVID-19 Pulmonary Sequelae and Management Considerations Journal of Personalized Medicine Post-COVID sequelae parenchymal abnormalities functional limitation rehabilitation |
| title | Long COVID-19 Pulmonary Sequelae and Management Considerations |
| title_full | Long COVID-19 Pulmonary Sequelae and Management Considerations |
| title_fullStr | Long COVID-19 Pulmonary Sequelae and Management Considerations |
| title_full_unstemmed | Long COVID-19 Pulmonary Sequelae and Management Considerations |
| title_short | Long COVID-19 Pulmonary Sequelae and Management Considerations |
| title_sort | long covid 19 pulmonary sequelae and management considerations |
| topic | Post-COVID sequelae parenchymal abnormalities functional limitation rehabilitation |
| url | https://www.mdpi.com/2075-4426/11/9/838 |
| work_keys_str_mv | AT afroditikboutou longcovid19pulmonarysequelaeandmanagementconsiderations AT andreasasimakos longcovid19pulmonarysequelaeandmanagementconsiderations AT elenikortianou longcovid19pulmonarysequelaeandmanagementconsiderations AT ioannisvogiatzis longcovid19pulmonarysequelaeandmanagementconsiderations AT argyristzouvelekis longcovid19pulmonarysequelaeandmanagementconsiderations |